MX2009011226A - Inhibidores especificos pdgfrbeta. - Google Patents

Inhibidores especificos pdgfrbeta.

Info

Publication number
MX2009011226A
MX2009011226A MX2009011226A MX2009011226A MX2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A
Authority
MX
Mexico
Prior art keywords
antagonists
pdgfrbeta
specific inhibitors
pdgfr
specific
Prior art date
Application number
MX2009011226A
Other languages
English (en)
Spanish (es)
Inventor
Zhenping Zhu
Juqun Shen
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of MX2009011226A publication Critical patent/MX2009011226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fuel Cell (AREA)
MX2009011226A 2007-04-17 2008-04-17 Inhibidores especificos pdgfrbeta. MX2009011226A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92397907P 2007-04-17 2007-04-17
PCT/US2008/005137 WO2008130704A2 (en) 2007-04-17 2008-04-17 PDGFRβ-SPECIFIC INHIBITORS

Publications (1)

Publication Number Publication Date
MX2009011226A true MX2009011226A (es) 2010-04-01

Family

ID=39837443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011226A MX2009011226A (es) 2007-04-17 2008-04-17 Inhibidores especificos pdgfrbeta.

Country Status (14)

Country Link
US (3) US7740850B2 (enExample)
EP (1) EP2139921A2 (enExample)
JP (1) JP5209702B2 (enExample)
KR (1) KR101136262B1 (enExample)
CN (1) CN101707882A (enExample)
AU (1) AU2008242444B2 (enExample)
BR (1) BRPI0810374A2 (enExample)
CA (1) CA2682390A1 (enExample)
EA (1) EA019595B1 (enExample)
IL (1) IL200779A0 (enExample)
MX (1) MX2009011226A (enExample)
NZ (1) NZ579734A (enExample)
UA (1) UA99608C2 (enExample)
WO (1) WO2008130704A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
SG2014015010A (en) * 2008-04-30 2014-05-29 Gradalis Inc Highly pure plasmid dna preparations and processes for preparing the same
US20120231537A1 (en) * 2008-04-30 2012-09-13 Gradalis, Inc. Highly Pure Plasmid DNA Preparations
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
AU2010299756A1 (en) * 2009-09-28 2012-04-19 Medizinische Universitat Wien PDGFRbeta inhibitors for use in the treatment of T-cell lymphoma
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP3798236B1 (en) 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CN107353342B (zh) * 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3271458A1 (en) 2015-03-20 2018-01-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Pericyte long non-coding rnas
WO2017106609A2 (en) * 2015-12-16 2017-06-22 Kadmon Corporation, Llc. Pdgfr beta antibody
MY200764A (en) 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JP7011657B2 (ja) 2016-10-30 2022-02-10 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｐｄ－ｌ１抗体および変異型
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018169785A2 (en) * 2017-03-13 2018-09-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Therapeutic antibodies to marburg virus
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
EP3758751A4 (en) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
DE102018204828A1 (de) 2018-03-29 2019-10-02 Ford Global Technologies, Llc Verhinderung von Glatteis durch Abwasser von Kraftfahrzeugen
RU2764740C1 (ru) 2018-08-09 2022-01-20 Бейцзин Уиздомаб Байотекнолоджи Ко., Лтд Биспецифическое антитело против вируса бешенства и его применение
US12098206B2 (en) 2018-10-05 2024-09-24 Seoul National University R&Db Foundation PDGF receptor antibody and use thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3170712A1 (en) * 2020-02-07 2021-08-12 Biorion Technologies B.V. Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof.
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白
CN118440214B (zh) * 2024-04-02 2025-01-28 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US20020009443A1 (en) 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6259971B1 (en) * 1997-06-30 2001-07-10 Compaq Computer Corporation Portable fuel-cell-powered system with ultrasonic atomization of H2O by-product
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2002027848A2 (de) * 2000-09-22 2002-04-04 Siemens Aktiengesellschaft Verfahren zum überwachen des medienaustritts aus einer brennstoffzelle und brennstoffzellenanlage
EP1313161A1 (en) * 2001-11-15 2003-05-21 Ballard Power Systems AG Fuel cell system and method for operating the same
US7582726B2 (en) * 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

Also Published As

Publication number Publication date
UA99608C2 (en) 2012-09-10
US20090053241A1 (en) 2009-02-26
CA2682390A1 (en) 2008-10-30
US20100221267A1 (en) 2010-09-02
JP2010524466A (ja) 2010-07-22
BRPI0810374A2 (pt) 2014-10-29
KR20090130382A (ko) 2009-12-23
AU2008242444A1 (en) 2008-10-30
US20110207005A1 (en) 2011-08-25
WO2008130704A3 (en) 2008-12-24
EA200970953A1 (ru) 2010-10-29
JP5209702B2 (ja) 2013-06-12
CN101707882A (zh) 2010-05-12
KR101136262B1 (ko) 2012-07-05
WO2008130704A2 (en) 2008-10-30
NZ579734A (en) 2012-01-12
US7740850B2 (en) 2010-06-22
AU2008242444B2 (en) 2013-05-02
IL200779A0 (en) 2010-05-17
EP2139921A2 (en) 2010-01-06
EA019595B1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
BR112015020466A2 (pt) inibidores de cdc7
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
AR102463A1 (es) Inhibidor de cinasa aurora a
PH12014502419A1 (en) Specific binding proteins and uses thereof
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
AR072699A1 (es) Antagonistas especificos del receptor 4 del factor de crecimiento de los fi-broblastos (fgf-r4)
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
EA201070822A1 (ru) Доставка антител посредством модульного домена распознавания
MX354743B (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
NZ703225A (en) Superior efficacy of cd37 antibodies in cll blood samples
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином

Legal Events

Date Code Title Description
FG Grant or registration